Search
Conestat alfa
go.drugbank.com/drugs/DB09228ApprovedC1 Esterase Inhibitor (Recombinant) is a recombinant analogue of endogenous complement component-1 esterase inhibitor (rhC1INH), purified from the milk of transgenic rabbits. … Additionally, C4 and C2 cleavage occurs resulting in auto-activation of the complement system.
Categories: Drugs Used in Hereditary AngioedemaRisperidone
go.drugbank.com/drugs/DB00734ApprovedInvestigationalRisperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. … [L12885] Schizophrenia and various mood disorders are thought to be caused by an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways
Products: RISPERIDON AL 1MG, RISPERIDON AL 2MGIcosapent ethyl
go.drugbank.com/drugs/DB08887ApprovedInvestigationalNutraceuticalIcosapent ethyl or ethyl eicosapentaenoic acid is a synthetic derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA). … FDA approved on July 26, 2012.
Synonyms: E-EPARemestemcel-L
go.drugbank.com/drugs/DB13973ApprovedInvestigationalWithdrawnRemestemcel-L is a third-party, off-the-shelf suspension of ex-vivo cultured adult human mesenchymal stem cells intended for intravenous infusion. … [L11022] Remestemcel-L was later approved by the FDA on December 18, 2024.
Synonyms: Remestemcel-LPropiverine
go.drugbank.com/drugs/DB12278ApprovedPropiverine is a widely used antimuscarinic drug with a mixed mode of action in the treatment of symptoms associated with overactive bladder (OAB) [A32576]. … OAB has a negative impact on quality of life and may lead to leakage and inconvenient urinary accidents [L2327], [L2328].
Products: PROPIVERIN AL 5MG, PROPIVERIN AL 15MGAdagrasib
go.drugbank.com/drugs/DB15568ApprovedInvestigational[A254052] In a phase I/IB clinical study that included patients with KRAS<sup>G12C</sup>-mutated advanced solid tumors (NCT03785249), adagrasib exhibited anti-tumor activity. … [A254052,A254057,A254946] In February 2022, the FDA accepted a new drug application (NDA) for adagrasib for the treatment of patients with previously treated KRAS<sup>G12C</sup>–positive NSCLC.
Naloxegol
go.drugbank.com/drugs/DB09049ApprovedInvestigationalNaloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. … It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain.
Categories: Compounds used in a research, industrial, or household settingAgomelatine
go.drugbank.com/drugs/DB06594ApprovedInvestigationalAgomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors, tested in an animal model of depression. … In 2006 Servier sold the rights to develop Agomelatine in the US to Novartis. The development for the US market was discontinued in October 2011.
Products: AGOMELATIN AL 25MG FTAUblituximab
go.drugbank.com/drugs/DB11850ApprovedInvestigationalallowing for administration in a one-hour infusion twice-a-year following the starting dose. … [A244210] Ublituximab is a chimeric anti-CD20 IgG1κ antibody produced in the rat YB2/0 cell line to target a unique epitope and enhance ADCC compared to other approved anti-CD20 antibodies such as [rituximab
Moxisylyte
go.drugbank.com/drugs/DB09205ApprovedMoxisylyte, denominated as thymoxamine in the UK, is a specific and orally active α1-adrenergic antagonist. … [L1172] This drug was developed by the Japanese company Fujirebio and also by the American company Iolab in the late 80s.
Categories: Drugs Used in Erectile Dysfunction